|  | 
| Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer. | 
|  | 
|  | 
| Consulting or Advisory Role - Oncolinea Pharmaceuticals | 
| Research Funding - Bayer (Inst); Janssen Scientific Affairs (Inst); Lantheus Medical Imaging (Inst); Progenics (Inst) | 
| Patents, Royalties, Other Intellectual Property - I am listed as inventor on patents related to PyIm polyamides that have been licensed by Gene Sciences | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Research Funding - Janssen (Inst); Lantheus Medical Imaging (Inst) | 
| Travel, Accommodations, Expenses - Varian Medical Systems | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
|  | 
| Travel, Accommodations, Expenses - Galera Therapeutics | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
|  | 
| Consulting or Advisory Role - Viewray | 
| Research Funding - ViewRay | 
|  | 
|  | 
| Stock and Other Ownership Interests  - ImaginAb | 
| Consulting or Advisory Role - Astellas Pharma | 
| Speakers' Bureau - Bayer Schering Pharma; Genomic Health; ImaginAb; Janssen Oncology; Pfizer | 
| Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst) | 
|  | 
|  | 
| Stock and Other Ownership Interests  - ViewRay | 
| Honoraria - Boston Scientific; Janssen Oncology; Varian Medical Systems; ViewRay; ViewRay | 
| Consulting or Advisory Role - Boston Scientific; Janssen | 
| Research Funding - Janssen Oncology (Inst); Point Biopharma (Inst); ViewRay; ViewRay | 
|  | 
|  | 
| Consulting or Advisory Role - Canon Medical System | 
| Research Funding - GE Healthcare (Inst); Lantheus Medical Imaging (Inst); Novartis (Inst); POINT Biopharma (Inst) | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Leadership - Aravalent; Survalent | 
| Stock and Other Ownership Interests  - Oncovalent Therapeutics; Survalent | 
| Consulting or Advisory Role - Ambrx; Amgen; INMune Bio; Precisca; Roivant | 
| Speakers' Bureau - Bayer; Johnson & Johnson | 
| Research Funding - Arvinas (Inst); Fortis (Inst); Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics | 
| Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet. | 
| Travel, Accommodations, Expenses - Johnson & Johnson |